Article Versions Notes

Amarù J, Barbieri F, Arvigo M, Solari A, Bajetto A, Nista F, Campana C, Gaggero G, Prior A, Criminelli Rossi D, et al. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST₂ in Mediating Ligand Effects. Cancers. 2021; 13(8):1816. https://doi.org/10.3390/cancers13081816

Amarù, Jessica, Federica Barbieri, Marica Arvigo, Agnese Solari, Adriana Bajetto, Federica Nista, Claudia Campana, Gabriele Gaggero, Alessandro Prior, Diego Criminelli Rossi, and et al. 2021. "Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST₂ in Mediating Ligand Effects" Cancers 13, no. 8: 1816. https://doi.org/10.3390/cancers13081816

Amarù, J., Barbieri, F., Arvigo, M., Solari, A., Bajetto, A., Nista, F., Campana, C., Gaggero, G., Prior, A., Criminelli Rossi, D., Zona, G., Ferone, D., Florio, T., & Gatto, F. (2021). Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST₂ in Mediating Ligand Effects. Cancers, 13(8), 1816. https://doi.org/10.3390/cancers13081816